Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
نویسندگان
چکیده
منابع مشابه
Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?
DOI: 10.5935/abc.20160009 In the first semester of this year, the U.S. Food and Drug Administration (FDA) approved a new drug for the treatment of heart failure, LCZ696, commercially known as Entresto. This new treatment option was evaluated by the FDA on a priority basis (fast track designation), which allowed a faster release than usual. In Brazil, the drug is being evaluated by the National ...
متن کاملPARADIGM-HF: Have we achieved a new paradigm in the treatment of heart failure?
PARADIGM-HF After several years of a disappointing series of negative clinical trials investigating novel therapies for systolic heart failure, the presentation of the landmark PARADIGM-HF [Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure] trial at the 2014 Congress of the European Society of Cardiology in Barcelona, with simultaneo...
متن کاملGeographic variations in the PARADIGM-HF heart failure trial
AIMS The globalization of clinical trials has highlighted geographic variations in patient characteristics, event rates, and treatment effects. We investigated these further in PARADIGM-HF, the largest and most globally representative trial in heart failure (HF) to date. METHODS AND RESULTS We looked at five regions: North America (NA) 602 (8%), Western Europe (WE) 1680 (20%), Central/Eastern...
متن کاملFat Grafting Technique, A Paradigm Shift in the Treatment of Tuberous Breast
BACKGROUND The tuberous breast syndrome is a condition that affects young women and can bring on serious disorders of self-esteem. There are numerous surgical techniques to correct this condition, but most of them include the use of breast implants to replace lack of volume. Nowadays, patients are increasingly becoming more demanding to get a definitive solution with minimal aesthetic sequelae...
متن کاملPARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure?
Heart failure (HF) is a global health problem with an estimated prevalence of over 5.8 million in the USA and over 23 million worldwide. It represents the most common cause of hospitalization in elderly patients (≥ 65 years) and its incidence has a growing trend mainly due to the aging of the population. Neurohumoral activation plays a major role in the pathophysiology. So in consequence, the c...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Arquivos Brasileiros de Cardiologia
سال: 2016
ISSN: 0066-782X
DOI: 10.5935/abc.20160009